Rigel Pharmaceuticals: 15min Chart Triggers MACD Death Cross, KDJ Death Cross

Rigel Pharmaceuticals's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross at 08/13/2025 13:45. This indicates that the stock price has the potential to continue declining, with a momentum shift towards the downside that could further exacerbate the decrease.

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has recently experienced a significant shift in its stock price momentum, as indicated by a MACD Death Cross and a KDJ Death Cross on its 15-minute chart on August 13, 2025, at 13:45. This technical indicator suggests that the stock price is poised for further decline, with the momentum trending towards the downside [1].

Rigel Pharmaceuticals reported strong financial results for the second quarter of 2025, with net product sales increasing by 76% year-over-year to $58.9 million. The company's total revenue for the quarter reached $101.7 million, including $42.7 million in contract revenues from collaborations. Notably, Rigel transitioned from a net loss of $1 million in the same period in 2024 to a net income of $59.6 million, highlighting its improved financial performance [1].

The company's TAVALISSE sales surged by 52% year-over-year to $40.1 million, driven primarily by an increase in new patient starts and improved patient affordability due to the Inflation Reduction Act. GAVRETO sales grew by 32% sequentially from Q1 2025 to $11.8 million, while REZLIDHIA sales increased by 36% year-over-year to $7 million [1].

Rigel Pharmaceuticals raised its total revenue guidance for 2025 to between $270 million and $280 million, reflecting anticipated growth of 45% to 52% compared to 2024. The company also increased its net product sales guidance for 2025 to $210 million to $220 million from the prior range of $185 million to $192 million [1].

However, the company faces challenges in maintaining growth momentum. The impact of improved patient affordability due to the Inflation Reduction Act may not be as strong in the second half of the year. Additionally, Rigel Pharmaceuticals decided not to exercise its right to share in future development expenses for ocadusertib, resulting in a $40 million non-cash revenue recognition [1].

In terms of technical indicators, Rigel Pharmaceuticals' 15-minute chart has recently exhibited a significant shift in momentum. On August 11, 2025, at 13:15, the stock experienced a MACD Death Cross and a KDJ Death Cross, suggesting that the stock price is poised for further decline, with the momentum of the stock price trending towards the downside. Investors may want to exercise caution and closely monitor the stock's performance [2].

References:
[1] https://finance.yahoo.com/news/rigel-pharmaceuticals-inc-rigl-q2-072906642.html
[2] https://za.investing.com/news/analyst-ratings/jefferies-raises-rigel-pharmaceuticals-stock-price-target-on-strong-sales-93CH-3822131